In continuation to earlier intimation dated March 11, 2020 and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, Cadila Healthcare has informed that the Board of Directors at its meeting held today, March 16, 2020 approved payment of interim dividend at of 350 %, that is, Rs 3.50 per equity share on 102,37,42,600 Equity Shares of Re 1 each of the Company for the Financial Year 2019-2020. The Board of Directors has confirmed Tuesday, March 24, 2020 as the Record Date to ascertain the list of members entitled to receive the interim dividend declared by the Board of Directors. Further, the interim dividend shall be paid to the shareholders entitled thereto, on and from March 27, 2020. The Dividend cheques would be posted on or after March 30, 2020 and within 30 days from the date of declaration of dividend as provided in the Companies Act, 2013.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: